Diagnosis and Management of Intrauterine Growth Restriction, Structural Anomalies and Chromosomal Anomalies: A Prospective Cohort Study

What this Trial Is About

This research aims to build a large platform combining clinical information and biological specimen banks for fetuses and infants diagnosed with intrauterine growth restriction (IUGR) or congenital anomalies. These conditions are significant causes of infant and childhood death, and this study seeks to understand their occurrence, progression, and relationship from before birth through early childhood. The goal is to provide a foundation for accurate diagnosis, precision treatment, and careful management of these conditions. Pregnant women and infants diagnosed with IUGR or various congenital anomalies (including structural and chromosomal anomalies) are enrolled. Routine obstetrical ultrasounds monitor fetal growth, and detailed maternal information, including dietary habits and exposures, is collected. After birth, infants receive appropriate treatments and regular physical and neurological examinations. Biological samples such as maternal blood, placenta, cord blood, infant blood, urine, stool, and tissues are collected and stored for research. Genetic testing is also conducted to explore disease causes and guide treatment. Participants undergo ongoing assessments including growth and development measurements, clinical outcome tracking, and evaluation of treatment effects on hospitalization and health. Data are collected via intelligent extraction platforms and analyzed using machine learning and statistical methods to improve prenatal diagnosis accuracy and identify prognostic markers. The study includes follow-ups up to several years to observe recovery and quality of life, supporting improved prevention and care strategies.

Diagnosis and Management of Intrauterine Growth Restriction and Congenital Anomalies